Objectives: The conducted studies were aimed at making a Polish adaptation of the Penn Alcohol Craving Scale (PACS) by B. Flannery and co-workers. The Scale is a self-assessment method, it comprises 5 statements, and is designed to assess alcohol craving experienced by a patient in a week prior to the examination.
Methods: 550 patients with diagnosed alcohol dependence syndrome were examined, and the final analysis included results of 510 persons. The examined group consisted of 396 men and 114 women. The study was made in the 3rd week of their alcohol treatment. There were used: the PENN Craving Scale, the Alcohol Dependence Development Scale (SRUA) (the part in which craving is dealt with), a clinical interview with specially prepared questions about alcohol craving experienced last month and last week, and the Yale-Brown Obsessive Compulsive Intense Drinking Scale.
Results: The Polish version of the Penn Scale is characterised by very good psychometric properties - it is a reliable and valid tool. The exploratory and confirmatory factor analyses have proved the existence of one factor. The internal consistency, assessed on the basis of Cronbach's alpha, equalled 0.89. The method displays statistically significant (majority p < 0.0010) relationships with levels of craving experienced last year, last month, and last week before the examination, and also with total score on the Yale-Brown Scale.
Conclusions: The effects of the conducted adaptation works on the Penn Scale speak for recommending the method for scientific research and use in therapeutic practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12740/PP/OnlineFirst/40548 | DOI Listing |
Addiction
January 2025
Addictions Department, School of Academic Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Background And Aims: This is the first systematic review of the extant literature on all major psychedelic-assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic-assisted treatment for AUD, TUD, and SUD; to evaluate its quality; and to offer recommendations for research.
Methods: This was a prospectively registered narrative systematic review of open-label, randomised controlled trials (RCT), and observational studies of d-lysergic acid diethylamide (LSD), mescaline, psilocybin, ayahuasca, ketamine, ibogaine and 3,4-methylenedioxymethamphetamine (MDMA).
Ther Adv Drug Saf
January 2025
Pharmacology Department, School of Medicine, University of Valladolid, Valladolid, Spain.
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years.
View Article and Find Full Text PDFSubst Use Misuse
January 2025
Psychological Sciences Department, Western Kentucky University, Bowling Green, KY, USA.
Background: Alcohol use among emerging adults is a public health concern, as it has been associated with numerous negative consequences. Poor sleep has repeatedly been associated with alcohol-related consequences in this age group, yet factors impacting this relationship and potential moderators remain largely unexplored.
Objectives: The primary objective of this study was to examine the indirect effect of poor sleep quality on alcohol-related consequences through alcohol craving and to determine whether depression moderates this association.
Drug Alcohol Depend Rep
March 2025
Radboud University, Postbus 9102, Nijmegen 6500 HC, the Netherlands.
Introduction: Ecological momentary assessment (EMA) is popular in smoking research to study time-varying processes and design just-in-time personalised cessation interventions. Yet, research examining the psychometric properties of EMA and user experiences with EMA protocols is lacking. We conducted a mixed-methods study to test the EMA component of a mobile intervention for middle to late-aged adolescents (16-20 years) who smoke cigarettes at least weekly.
View Article and Find Full Text PDFSleep Med Rev
January 2025
Faculty of Medicine, Department of Psychiatry, University of Geneva, Geneva, Switzerland.
Insomnia is prevalent among patients with alcohol use disorder (AUD), potentially undermining treatment and increasing the risk of relapse. Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for insomnia, but its efficacy is not well-characterized in patients across the spectrum of AUD. The aim of this meta-analysis was to quantify the effectiveness of CBT-I in improving insomnia severity and alcohol-related outcomes in adults with heavy alcohol use and/or varying levels of AUD severity and comorbid insomnia.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!